Pioglisant (30 mg) Pioglitazone > Ọgwụgwọ na mgbochi

Mbadamba 15 mg, 30 mg

Otu mbadamba ihe

ike ihe - pioglitazone hydrochloride 16.53 mg (nke kwekọrọ na pioglitazone 15.00 mg) maka usoro onunu ogwu nke 15 mg, ma obu 33.06 mg (30.00 mg) maka onunu ogwu nke 30 mg,

ndị mbụ: lactose monohydrate, calcium carmellose, hydroxypropyl cellulose, magnesium stearate.

Mbadamba dị ọcha ma ọ bụ ihe fọrọ nke nta ka ọ bụrụ na-acha ọcha, gburugburu na biconvex elu (maka usoro onunu ogwu nke 15 mg), mbadamba ahụ na-acha ọcha ma ọ bụ ihe fọrọ nke nta ka ọ bụrụ ọcha, okirikiri, cylindrical dị larịị na akara ngosi n'ụdị obe (maka usoro nke 30 mg).

Ngwongwo ogwu

Mlọ ọgwụ

Ọkpụkpọ nke pioglitazone na metabolites na-arụ ọrụ n'ime ọbara ọbara na-anọgide n'ọkwa dị elu awa iri abụọ na anọ mgbe otu ọgwụ kwa ụbọchị. A na-ebute nchịkọta nke pioglitazone na pioglitazone (pioglitazone + metabolites na-arụ ọrụ) n'ime ụbọchị asaa. Nchịkwa ugboro ugboro anaghị eduga nchịkọta nke ogige ma ọ bụ metabolites. Oke ntinye uche na serum (Cmax), mpaghara dị n'okpuru usoro (AUC) na ntinye uche dị ala na ọbara (Cmin) nke pioglitazone na ngụkọta pioglitazone na-abawanye na nha iji 15 mg na 30 mg kwa ụbọchị.

Mgbe nchịkwa ọnụ gachara, a na-enweta pioglitazone ngwa ngwa site na eriri afọ, kpebisiri ike n'ọbara ọbara mgbe nkeji 30 gasịrị, a na-erube ọnụ ọgụgụ kachasị elu mgbe awa 2 gasịrị. Ntinye ọgwụ ahụ kwụsịrị ị nweta nri. Ezigbo bioavailability karịrị 80%.

Odi nkenke nke nkesa ọgwụ n’ahu bu 0.25 l / kg. Pioglitazone na metabolites ya na-arụ ọrụ na-emetụta njikọta plasma (> 99%).

Metabolism A na - enweta pioglitazone site na hydroxylation na oxidation, a na - agbanwekwa metabolites akụkụ ụfọdụ na glucuronide ma ọ bụ sulfate conjugates. M metabolite M-II na M-IV (usoro hydroxy nke pioglitazone) na M-III (keto nke pioglitazone) nwere ọrụ ọgwụ.

Na mgbakwunye na pioglitazone, M-III na M-IV bụ anụ ndị metụtara ọgwụ ndị akọwapụtara n'ọbara mmadụ mgbe ejiri ọgwụ ahụ ugboro ugboro. A maara na ọtụtụ isoforms nke cytochrome P450 na-etinye aka na metabolism nke pioglitazone. Mmezu ahụ gụnyere cytochrome P450 isoforms dịka CYP2C8 yana, n'obere obere, CYP3A4, na ntinye ndị ọzọ nke isoforms ndị ọzọ, gụnyere CYP1 extrahepatic.

Mgbe nchịkwa ọnụ gachara, ihe dị ka pacenti 45% nke pioglitazone bụ mmamịrị, 55% na feces. Mkpuchi nke pioglitazone site na akụrụ bụ nke a na - eleghara anya, ọkachasị n'ụdị metabolites na conjugates ha. Ndụ ọkara nke pioglitazone bụ 5-6 awa, ngụkọta pioglitazone (pioglitazone + metabolites na-arụ ọrụ) bụ awa 16-23.

Ndị otu ọrịa pụrụ iche

Ọkara ndụ nke pioglitazone site na ọbara ọbara na-anọgide na-agbanweghi agbanwe na ndị ọrịa nwere oke (klọdine 30-60 ml / min) na nnukwu (mwepụ creatinine 4 ml / min). Onweghi ozi banyere iji ọgwụ maka ọgwụgwọ nke ndị ọrịa na - arịa ọrịa akwara, ya mere ekwesighi iji Pioglisant na-emeso otu ndị ọrịa.

Imeju imejuA na - ebute ọrịa ime ahụ na ndị ọrịa nwere ọrịa imeju.

Nkọwapụta nke ọgwụ ọgwụ

Selectively na-akpali nuklia gamma ndị na-anabata rụọ ọrụ site na peroxisome proliferator (gamma PPAR). Ọ na-emegharị mkpụrụ ndụ ihe nketa nke na-emetụta insulin ma na-etinye aka na nchịkwa nke ọkwa glucose na metabolism lipid na adipose, akwara anụ ahụ na imeju. Ọ naghị eme ka insulin too uto, ka o sina dị, ọ na-arụ ọrụ naanị mgbe echekwara ọrụ insulin-synthetic nke pancreas. Na-ebelata insulin iguzogide akwara anụ ahụ na imeju, na-abawanye oriri nke glucose na-adabere, belata mmepụta nke glucose site na imeju, na-ebelata ọkwa nke glucose, insulin na haemoglobin glucose dị n'ọbara. N'ime ndị ọrịa nwere metabolism ike, ọ na-ebelata triglycerides ma na-abawanye HDL na-enweghị na-agbanwe LDL na cholesterol zuru ezu.

N'ime ihe omumu nyocha, o nweghi uto carcinogenic na mutagenic. Mgbe etinyere ụmụ oke na ụmụ oke ruru 40 mg / kg / ụbọchị, pioglitazone (ihe ruru ugboro 9 karịa nke MPDC, gbakọọ na 1 m2 nke anụ ahụ), enweghị mmetụta ọ bụla na ọmụmụ.

Ihe ngosi maka ojiji

2dị ọrịa shuga abụọ:
- na monotherapy na ndị ọrịa nwere oke ibu na nri adịghị arụ ọrụ na mmega ahụ na ekweghị na metformin ma ọ bụ ọnụnọ nke contraindication maka iji ya,
- dịka akụkụ nke ọgwụgwọ ngwakọta:

1. na metformin na ndị ọrịa nwere oke ibu na enweghị nchịkwa nchịkwa zuru oke na ndabere nke metformin monotherapy,
2. Site na usoro sulfonylurea naanị na ndị ọrịa maka metformin ka contraindicated, na enweghị enweghị nchịkwa glycemic zuru oke megide ndabere nke monotherapy na usoro sulfonylurea.
3. na insulin na-enweghị ezigbo njikwa glycemic n'oge ọgwụgwọ na insulin na ndị ọrịa nke metformin contraindicated.

Mlọ ọgwụ

Thiazolidinedione hypoglycemic nnọchite maka ọnụ eji.

Pioglitazone na-akpali kpọmkwem ndị na-anabata gamma ndị nọ na ntanetị, nke onye na - eme mkpọtụ peroxisome na - arụ ọrụ (PPARγ). Ọ na-emegharị mkpụrụ ndụ ihe nketa nke na-emetụta insulin ma na-etinye aka na nchịkwa nke ịta ọbara glucose na metabolism metabolism na adipose, akwara anụ ahụ na imeju. N'adịghị ka nkwadebe ndị a na-enweta na sulfonylureas, pioglitazone adịghị akpali insulin insulin, mana ọ na-arụ ọrụ naanị mgbe echekwara ọrụ insulin na-arụ ọrụ nke pancreas. Pioglitazone na-ebelata insulin iguzogide na akwara anụ ahụ na imeju, na-eme ka oriri nke insulin na-adabere ma belata mwepụta glucose site na imeju, na -ebelata mkpụkọ glucose, insulin na haemoglobin glycosylated. N'oge ọgwụgwọ na pioglitazone, mkpokọta nke triglycerides na abụba abụba na plasma ọbara na-ebelata, ntinye uche nke lipoproteins dị ukwuu na-abawanye.

Maka ndị ọrịa nwere ọrịa shuga nke 2, a na-emeziwanye ohere ịba ụba glucose ọbara na afọ na-enweghị isi na mgbe nri gasịrị.

Mlọ ọgwụ

Pioglitazone na-abanye ngwa ngwa, Cmax nke pioglitazone na plasma ọbara na-erukarị awa 2 mgbe nchịkwa ọnụ. N’ime usoro onunu ogwu, ihe ndi n’aru plasma na abawanye karie ka odi elu. Site na nchịkwa nchịkwa ugboro ugboro, pioglitazone na metabolites adịghị eme. Iri nri anaghị emetụta mmịpụta. Bioavailability karịrị 80%.

Vd bụ 0.25 l / n'arọ ahụ wee rụpụta ya mkpụrụ ụbọchị 4-7 ka ebidochara ọgwụgwọ. Ihe jikọtara protein protein nke pioglitazone karịrị 99%, metabolites ya - karịa 98%.

Pioglitazone bụ metabolized site na hydroxylation na oxidation. Imirikiti usoro a na - eme na ntinye nke cytochrome P450 isoenzymes (CYP2C8 na CYP3A4), yana, n'otu oge, dịtụ obere, ndị ọzọ na - anọpụ iche. 3 n'ime 6 mara metabolites (M) gosipụtara ọrụ ọgwụ (M-II, M-III, M-IV). Nyere oru ogwu, ntinye uche na ogo nke ijigide na protein ndi plasma, pioglitazone na metabolite M-III mezue n’agha n’oru aka, ntinye nke metabolite M-IV n’oru zuru oke nke ogwu ahu di ka okpukpu ato kariri inye onyinye pioglitazone, na mmekorita nke metabolite M-II buru ihe pere mpe. .

Na nyocha nke vitro egosila na pioglitazone anaghị egbochi ọnụnọ nke CYP1A, CYP2C8 / 9, CYP3A4.

Ọ bụ ihe dị na ya bụ na eriri afọ ya, yana akụrụ (15-30%) n'ụdị metabolites na conjugates ha. T1 / 2 nke pioglitazone na-agbanweghi agbanwe na plasma ọbara dị ka awa 3-7, yana maka metabolites niile na-arụ ọrụ ruo elekere 16-24.

Theta ahụ na pioglitazone na metabolites na-arụ ọrụ na plasma ọbara na-anọgide na ọkwa dị elu maka awa 24 mgbe otu nchịkwa kwa ụbọchị.

Pharmacokinetics n'ihe gbasara ọrịa

Ọrịa ndị agadi na / ma ọ bụ na-arụ ọrụ ezigharị adịghị arụ ọrụ, achọrọ ịmegharị dose.

Na-emegide usoro ọrụ imeju na-emebi emebi, obere nke pioglitazone dị elu.

Jiri maka ọrụ ezighi ezi na-arụ ọrụ

Maka ndị ọrịa nwere nsogbu gbasara akụrụngwa (mwepụ nke creatinine karịrị 4 ml / min), a chọghị ndozi dose. Enweghị data banyere iji pioglitazone na ndị ọrịa na-anata ọgwụgwọ hemodialysis. Ya mere, ekwesighi iji pioglitazone na ìgwè ndị ọrịa a.

- ọdịda ọdịda na-adịghị ala ala (CC na-erughị 4 ml / min).

Ihe ngbanwe

- ụdị shuga 1
- ọrịa mamịrị ketoacidosis,
- nkụda obi, gụnyere akụkọ ihe mere eme (Klas nke I-IV dịka nhazi ọkwa NYHA),
- imeju imeju (ịmụba ọrụ nke imeju na-agbakarị okpukpu abụọ karịa elu karịa nke nkịtị),
- odida obere akwara na-adịghị ala ala (CC erughị 4 ml / min),
- ụkọ lactase, nnagide nri nke lactose, glucose-galactose malabsorption,
- afọ ime
- oge ọmụmụ,
- ụmụaka na-erubeghị afọ 18 (a naghị eduzi ọmụmụ banyere ọgwụgwọ na arụmọrụ nke pioglitazone na ụmụaka),
- Hypersensitivity na pnoglitazone ma ọ bụ akụkụ ndị ọzọ nke ọgwụ.

Iji nlezianya na - edematous syndrome, anaemia.

Jiri n'oge ime na lactation. Agụbeghị ịdị irè na nchekwa nke pioglitazone n'ime ụmụ nwanyị dị ime, ya mere, a machibidoro iji ọgwụ ahụ n'oge ime. Egosiwo Pioglitazone ka ogo nwa ebu n'afọ na-eto ngwa ngwa. Amaghị ma pioglitazone dị na mmiri ara ara, yabụ, ụmụ nwanyị ekwesịghị ị notụ ọgwụ ahụ n'oge a na-enye ya ara. Ọ bụrụ na ọ dị mkpa, nhọpụta nke ọgwụ n’oge a na-enye ya ara, a ga-akwụsị ịhapụ inye ya ara.

Nsonaazụ

Site na akụkụ ahụ nwere mmetụta: oge - imerụ ahụ anya.

Site na sistem iku ume: ọtụtụ mgbe - ọrịa ọrịa akụkụ okuku ume na-adịkarị ala - sinusitis.

Site n'akụkụ nke metabolism: mgbe mgbe - ịba ụba n’arụ ahụ.

Site na sistemụ ụjọ: ọtụtụ mgbe - hypesthesia, ugboro ugboro - ehighi ura.

Nchikota pioglitazone na metformin

Site na akwara hemopoietic: ọtụtụ mgbe - anaemia.

Site na akụkụ ahụ nwere mmetụta: oge - imerụ ahụ anya.

Site na usoro nri: enweghi oge - flatulence.

Site n'akụkụ nke metabolism: mgbe mgbe - ịba ụba n’arụ ahụ.

Site na usoro akwara: mgbe mgbe - arthralgia.

Site na usoro ụjọ: mgbe ụfọdụ - isi ọwụwa.

Site na usoro genitourinary: ọtụtụ mgbe - hematuria, dysfunction erectile.

Njikọ nke pioglitazone na sulfonylureas

Site na akụkụ anụ ahụ nke anụ ahụ: oge ụfọdụ - vertigo, enweghi ike ịhụ ụzọ.

Site na usoro digestive: ọtụtụ mgbe - flatulence.

Ndị ọzọ: enweghi oge - ike ọgwụgwụ.

Site na akụkụ nke metabolism: mgbe mgbe - ịba ụba ahụ, ugboro ugboro - ịba ụba nke lactate dehydrogenase, agụụ nri, hypoglycemia.

Site na sistemụ ụjọ: ọtụtụ mgbe - ọgbụgba, enweghị oge - isi ọwụwa.

Site na usoro mkpụrụ ndụ: enweghi oge - glucosuria, proteinuria.

Site na anụ ahụ: ugboro ugboro - ịba ụba aja.

Nchikota pioglntazone na metformin na sulfonylureas

Site na akụkụ nke metabolism: ọtụtụ mgbe - hypoglycemia, mgbe mgbe - ịba ụba ahụ, ụba ọrụ nke creatine phosphokinase (CPK).

Site na usoro akwara: mgbe mgbe - arthralgia.

Nchikota pioglitazone na insulin

Site n'akụkụ nke metabolism: mgbe mgbe - hypoglycemia.

Site na usoro akwara: mgbe mgbe - mgbu azụ, arthralgia.

Site na usoro iku ume: ọtụtụ mgbe - ume mkpụmkpụ, ọnya afọ.

Site na sisitemu obi: otutu mgbe - odida obi.

Ihe ozo: otutu mgbe - edema.

N’akụkụ akụkụ anụ ahụ nke anụ ahụ: amabeghị ugboro ole - ọzịza nke macula, okpukpu ọkpụkpụ.

Site na iji pioglitazone ruo ogologo oge maka ihe karịrị 1 afọ na 6-9% nke ikpe, ndị ọrịa nwere edema, dị nro ma ọ bụ agafeghị oke, na-anaghị achọ ịkwụsị ọgwụgwọ.

Ọrịa nlegharị anya na-aputa ihe na mmalite nke ọgwụgwọ ma jikọtara ya na mgbanwe na plasma ịta ahụ, dịka ndị ọrịa hypoglycemic ndị ọzọ.

Usoro onunu ogwu na nhazi

N'ime oge 1 / n'agbanyeghị nri nri.

Usoro ọgwụgwọ akwadoro na-atụ aro bụ 15 ma ọ bụ 30 mg 1 oge / Ngwọta kachasị maka monotherapy bụ 45 mg, yana ọgwụ nchịkọta 30 mg.

Mgbe ị na-edepụta pioglitazone yana nchịkọta metformin, enwere ike ịga n’ihu n’ịchịkwa nke metformin.

Na ntinye ndi mmadu na mmanu sulfonylurea: na nmalite ogwugwo, enwere ike isi n’iru ha dozie ya. N'ihe banyere hypoglycemia, a na-atụ aro ka ịgbanye ọgwụ mgbochi nke sulfonylurea.

Na insulin: ọgwụ mbu nke pioglitazone bụ 15-30 mg /, dose insulin na-adịgide otu ma ọ bụ belata 10-25% mgbe hypoglycemia mere.

Maka ndị ọrịa agadi, ọ chọghị ime mgbanwe dose.

Ekwesighi iji Pioglitazone na ndị ọrịa nwere nsogbu imeju.

Enweghị data maka iji pioglitazone na ndị ọrịa na-erubeghị afọ 18, yabụ akwadoghị iji pioglitazone na otu ọgbọ a.

Mmekọrịta na ọgwụ ndị ọzọ

Mgbe ị na-eji pioglitazone yana ọgwụ hypoglycemic ọgwụ ndị ọzọ, mmepe nke hypoglycemia ga-ekwe omume. N'okwu a, ịbelata mmịnye ọgwụ ọzọ hypoglycemic ọgwụ nwere ike ịchọ.

Na-emegide usoro ojiji nke pioglitazone jikọtara ya na insulin, mmepe nke nkụda obi nwere ike ikwe omume.

Pioglitazone emetụtaghị ọgwụ pharmacokinetics na pharmacodynamics nke glipizide, digoxin, warfarin, metformin.

Gemfibrozil na-abawanye uru AUC nke pioglitazone ugboro atọ.

Rifampicin na-eme ka metabolism nke pioglitazone jiri 54%.

Na vitro ketoconazole na-egbochi metabolism nke pioglitazone.

Ntụziaka pụrụ iche maka nnabata

Mgbe ị na-emeso ụdị ọrịa shuga mellitus nke 2, na mgbakwunye na ịioụ pioglitazone, a na-atụ aro ịgbaso usoro nri na mmega ahụ iji nọgide na-adị irè nke ọgwụ ọgwụ, yana n'ihe metụtara ịrị elu nke ahụ.

Site n'iji pioglitazone, njigide mmiri na mmụba na olu plasma ga - ekwe omume, nke nwere ike iduga mmepe ma ọ bụ njọ nke nkụchi obi, yabụ, ọ bụrụ na ọnọdụ nke usoro akwara obi na-akawanye njọ, ekwesịrị ịkwụsị pioglitazone.

Ndị ọrịa nwere ọ dịkarịa ala otu ihe ọghọm maka mmepe nke nkụda obi na-adịghị ala ala (CHF) kwesịrị ịmalite ọgwụgwọ na obere opekata mpe ma jiri nwayọ bulie ya. Ọ dị mkpa ịchọpụta ihe mgbaàmà mbụ nke nkụda obi, oke ibu (nwere ike igosipụta mmepe nke nkụchi obi) ma ọ bụ mmepe nke edema, ọkachasị ndị ọrịa nwere nrụpụta gbasara obi. N'ihe banyere mmepe nke CHF, a na-akagbu ọgwụ ahụ ozugbo.

Pioglitazone nwere ike ibute ọrụ imeju. Tupu ọgwụgwọ na oge ụfọdụ n'oge usoro ọgwụgwọ, a ga-enyocha ọrụ enzyme imeju. Ọ bụrụ na ihe omume ALT karịrị ugboro abụọ karịa oke nke kwesịrị, ma ọ bụ ọnụnọ nke mgbaàmà ndị ọzọ nke imeju, a na-egbochi pioglitazone.Ọ bụrụ na, na usoro ọmụmụ abụọ, usoro ọrụ AlT gafere oke nke ụkpụrụ ahụ site na oge 3 ma ọ bụ onye ọrịa ahụ tolitere jaundice, a na-akwụsị ọgwụgwọ na pioglitazone ozugbo. Ọ bụrụ na onye ọrịa ahụ nwere ihe mgbaàmà na-egosi ọrụ imeju na-arịa ya (ọgbụgbọ na-enweghị nkọwa, ọgbụgbọ, mgbu afọ, adịghị ike, anorexia, mmamịrị gbara ọchịchịrị), a ga-enyocha ọrụ nke enzymes imeju ozugbo.

Pioglitazone nwere ike ibute hemoglobin ma ọ bụ hematocrit site na 4% na 4.1%, otu osi dị, nke nwere ike ịbụ n'ihi hemodilution (n'ihi njigide mmiri).

Pioglitazone na - eme ka insulin nwee anụ ahụ, nke a na - eme ka ịbawanye hypoglycemia n'ahụ na ndị ọrịa na - anata ọgwụgwọ nchikota nke nwere ụdị sulfonylurea ma ọ bụ insulin. Nwere ike ịbelata usoro nke nke ikpeazụ.

Pioglitazone nwere ike ibute ma ọ bụ mebie ede macical edema, nke nwere ike ibute mbelata visual acuity.

Pioglitazone nwere ike ịbawanye ohere nke mgbaji na ụmụ nwanyị.

N'ime ndị ọrịa nwere ọrịa polycystic ovary syndrome, ịmụba insulin na-aba ụba nwere ike ibute ịmaliteghachi nke ovulation na o kwere omume ịtụrụ ime. Ndị ọrịa nwere polycystic ovary syndrome ndị na-achọghị ịtụrụ ime kwesịrị iji ụzọ ịtụkwasị obi nke igbochi afọ ime. Ọ bụrụ na ime dị, a ga-akwụsị ọgwụgwọ ozugbo.

Mmetụta ikike ịkwọ ụgbọ ala na usoro nchịkwa

N'inye nsogbu ndị dị na ọgwụ ahụ, a ga-akpachara anya mgbe ị na-anya ụgbọ ala ma na-arụ ọrụ ndị chọrọ ịta ahụhụ.

Etu esi eji: usoro onunu ogwu na usoro ọgwụgwọ

Were ọnụ kwa ụbọchị 1 kwa ụbọchị, n'agbanyeghị nri ị ga-eri.

Usoro ọgwụgwọ akwadoro ịmalite bụ 15 ma ọ bụ 30 mg otu ugboro kwa ụbọchị. Oke kachasị kwa ụbọchị maka monotherapy bụ 45 mg, yana ọgwụgwọ njikọta - 30 mg.

Mgbe ị na-ede Piouno na metformin, enwere ike ịga n’ihu n’ịchịkwa nke metformin.

Na ntinye ndi mmadu na mmanu sulfonylurea: na nmalite ogwugwo, enwere ike isi n’iru ha dozie ya. N'ihe banyere hypoglycemia, a na-atụ aro ka ịgbanye ọgwụ mgbochi nke sulfonylurea.

Na insulin: usoro mbu nke pioglitazone bụ 15-30 mg kwa ụbọchị, dose insulin na-adịgide otu ma ọ bụ belata 10-25% mgbe hypoglycemia mere.

Maka ndị ọrịa agadi, ọ chọghị ime mgbanwe dose.

Ekwesighi iji Pioglitazone na ndị ọrịa nwere nsogbu imeju.

Enweghị data maka iji pioglitazone na ndị ọrịa na-erubeghị afọ 18, a naghị atụ aro iji pioglitazone na otu ọgbọ a.

Omume ọgwụ

Ngalaba Piouno nọ n'ọrụ bụ pioglitazone, onye nnọchi anya hypoglycemic nke usoro thiazolidinedione maka nchịkwa ọnụ.

Pioglitazone na-akpali kpọmkwem ndị nabatara gamma ndị na-anabata ya na ntanetị, nke onye na - eme mkpọtụ peroxisome na - arụ ọrụ (PPAR gamma). Ọ na-emegharị mkpụrụ ndụ ihe nketa nke na-emetụta insulin ma na-etinye aka na nchịkwa nke ịta ọbara glucose na metabolism metabolism na adipose, akwara anụ ahụ na imeju. N'adịghị ka nkwadebe ndị a na-enweta na sulfonylureas, pioglitazone adịghị akpali insulin insulin, mana ọ na-arụ ọrụ naanị mgbe echekwara ọrụ insulin na-arụ ọrụ nke pancreas. Pioglitazone na-ebelata insulin iguzogide na akwara anụ ahụ na imeju, na-eme ka oriri nke insulin na-adabere ma belata mwepụta glucose site na imeju, na -ebelata mkpụkọ glucose, insulin na haemoglobin glycosylated. N'oge ọgwụgwọ na pioglitazone, mkpokọta nke triglycerides na abụba abụba na plasma ọbara na-ebelata, ntinye uche nke lipoproteins dị ukwuu na-abawanye.

Maka ndị ọrịa nwere ọrịa shuga nke 2, a na-emeziwanye ohere ịba ụba glucose ọbara na afọ na-enweghị isi na mgbe nri gasịrị.